3SBIO Sees Slowdown In China Regulatory Approvals Following SFDA Restructure; Concerns Linger On Drug Pricing Examination
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Chinese biotech outfit 3SBio reported strong sales growth of its key products, recombinant human erythropoietin injection EPIAO and recombinant human thrombopoietin injection TPIAO, but like many companies in China, 3SBio's development plans are impacted by a regulatory slowdown caused by restructuring at China's State FDA
You may also be interested in...
Chinese Year Of The Rabbit Expected To Speed Up New Drug Approvals
China's State FDA is expected to focus on new drug approvals this year in an attempt to get through its backlog of approval registrations.
Chinese Year Of The Rabbit Expected To Speed Up New Drug Approvals
China's State FDA is expected to focus on new drug approvals this year in an attempt to get through its backlog of approval registrations.
Chinese Year Of The Rabbit Expected To Speed Up New Drug Approvals
SHANGHAI - China's slow drug approvals, which can take as long as two years, are expected to speed up considerably in the Chinese Year of the Rabbit. China's State FDA is expected to focus on new drug approvals this year in an attempt to get through its backlog of approval registrations